Effects of Fuzheng Huayu recipe on entecavir pharmacokinetics in normal and dimethylnitrosamine-induced hepatic fibrosis rats
暂无分享,去创建一个
Tao Yang | Chang-hong Wang | Y. Tao | Tian-hui Zheng | Shuping Li | Wei Liu | Qiang Zhao | Chenghai Liu | Cheng-hai Liu
[1] M. Buti,et al. Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population. , 2018, Journal of hepatology.
[2] J. Pavlik,et al. Entecavir Interacts with Influx Transporters hOAT1, hCNT2, hCNT3, but Not with hOCT2: The Potential for Renal Transporter-Mediated Cytotoxicity and Drug–Drug Interactions , 2016, Front. Pharmacol..
[3] Cheng-Hai Liu,et al. Comparative pharmacokinetic and tissue distribution profiles of four major bioactive components in normal and hepatic fibrosis rats after oral administration of Fuzheng Huayu recipe. , 2015, Journal of pharmaceutical and biomedical analysis.
[4] T. Yang,et al. Comparative pharmacokinetics and tissue distribution profiles of lignan components in normal and hepatic fibrosis rats after oral administration of Fuzheng Huayu recipe. , 2015, Journal of ethnopharmacology.
[5] M. A. Wouters,et al. Potential role of glutathione in evolution of thiol-based redox signaling sites in proteins , 2015, Frontiers in Pharmacology.
[6] S. Ahn,et al. Performance evaluation of the HepB Typer-Entecavir kit for detection of entecavir resistance mutations in chronic hepatitis B , 2013, Clinical and molecular hepatology.
[7] Tao Yang,et al. Investigation of the absorbed and metabolized components of Danshen from Fuzheng Huayu recipe and study on the anti-hepatic fibrosis effects of these components. , 2013, Journal of ethnopharmacology.
[8] Huijun Sun,et al. OAT1 and OAT3: targets of drug-drug interaction between entecavir and JBP485. , 2013, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[9] D. H. Sweet,et al. Competitive inhibition of human organic anion transporters 1 (SLC22A6), 3 (SLC22A8) and 4 (SLC22A11) by major components of the medicinal herb Salvia miltiorrhiza (Danshen). , 2013, Drug metabolism and pharmacokinetics.
[10] A. Davey,et al. Salting-out homogeneous liquid-liquid extraction approach applied in sample pre-processing for the quantitative determination of entecavir in human plasma by LC-MS. , 2012, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[11] Ying He,et al. Food effect on the pharmacokinetics of entecavir from dispersible tablets following oral administration in healthy Chinese volunteers , 2010, Arzneimittelforschung.
[12] Yue Zhang,et al. Fuzheng Huayu recipe and vitamin E reverse renal interstitial fibrosis through counteracting TGF-beta1-induced epithelial-to-mesenchymal transition. , 2010, Journal of ethnopharmacology.
[13] Yi-Yang Hu,et al. Effect of Fuzheng Huayu formula and its actions against liver fibrosis , 2009, Chinese medicine.
[14] J. Pawlotsky. EASL Clinical Practice Guidelines. , 2009, Journal of hepatology.
[15] Jörg Petersen,et al. EASL Clinical Practice Guidelines: management of chronic hepatitis B. , 2009, Journal of hepatology.
[16] E. Palumbo. New Drugs for Chronic Hepatitis B: A Review , 2008, American journal of therapeutics.
[17] S. J. Matthews,et al. Entecavir for the treatment of chronic hepatitis B virus infection. , 2006, Clinical therapeutics.
[18] Xun Hu,et al. Dibenzocyclooctadiene lingnans: a class of novel inhibitors of P-glycoprotein , 2006, Cancer Chemotherapy and Pharmacology.
[19] H. Van Vlierberghe,et al. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. , 2002, Gastroenterology.
[20] P. Scheuer,et al. Classification of chronic viral hepatitis: a need for reassessment. , 1991, Journal of hepatology.